In addition to two IL-17A inhibitors, brodalumab, an antibody directly against IL-17RA, has been used in treating psoriasis.30 Two phase III studies (AMAGINE-2 and AMAGINE-3) showed that, after the use of brodalumab via subcutaneous injection at 210 mg once every other week, the PASI 75 response rates were 85.0% and 86.0% at week 12 of treatment.457 In addition to plaque psoriasis, brodalumab is also effective in the treatment of articular psoriasis.458,459. This evidence concerns the gene IL17A and psoriasis vulgaris.